Clinical Trial Update: Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating regorafenib in combination with Yttrium-90 radioembolization for unresectable hepatocellular carcinoma. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Stivarga (regorafenib)
• Yttrium-90 radioembolization (yttrium-90 microspheres)

Snippet

Sponsor: University of Miami | Conditions: Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING